<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01604785</url>
  </required_header>
  <id_info>
    <org_study_id>Meckler01</org_study_id>
    <nct_id>NCT01604785</nct_id>
  </id_info>
  <brief_title>Low-dose Propofol for Pediatric Migraine</brief_title>
  <official_title>Low-dose Propofol for Abortive Therapy of Pediatric Migraine in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Propofol, a general anesthetic, has been suggested to be effective for the treatment of
      migraine headaches in adults when used in subanesthetic doses (lower doses than those used
      for anesthesia or sedation). Initial retrospective review of the investigators experience
      with propofol for migraine in children suggests that it is safe and may be more effective
      than standard treatments used in the emergency department. The investigators retrospective
      series had a small subject population and a larger study is needed to compare propofol to
      current available treatments.

      Standard treatment currently consists of a &quot;cocktail&quot; of medications that include anti-nausea
      medicines (metoclopramide and diphenhydramine) and an analgesic (ketorolac) as well as
      intravenous fluids. Subjects assigned to the experimental group (Propofol) will receive the
      same intravenous fluids and up to five doses of propofol. All subjects will undergo
      assessment of their pain (self-rated on a scale from 0-10) before and after treatment.
      Post-visit clinical data will be collected from the subject's medical record and subjects
      will be called by telephone 24-48 hours after discharge from the emergency department to ask
      how they are doing and whether they required any additional treatments such as home
      medications or by other medical professionals other than OHSU.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There has been little advancement in abortive migraine therapies in recent decades, and few
      proven treatments exist for acute migraine, particularly in children. Propofol, a general
      anesthetic, has been suggested to be effective for the treatment of migraine headaches in
      adults when used in subanesthetic doses (lower doses than those used for anesthesia or
      sedation). Initial retrospective review of the investigators experience with propofol for
      migraine in children suggests that it is safe and may be more effective than standard
      treatments used in the emergency department. The investigators retrospective series had a
      small subject population and a larger study is needed to compare propofol to current
      available treatments.

      All subjects presenting to the pediatric emergency department with signs/symptoms of migraine
      headache will be screened for the study. Subjects who are eligible will be provided
      information about the study and consent/assent forms from a member of the research team, and
      asked whether they are interested in participating.

      All study subjects will receive acetaminophen (Tylenol) or ibuprofen (Motrin) for their
      headache if they have not already tried these first-line treatments at home; those with
      persistent symptoms requiring further treatment who consent to participate in the study will
      be randomized to receive either standard treatment or propofol. Standard treatment currently
      consists of a &quot;cocktail&quot; of medications that include anti-nausea medicines (metoclopramide
      and diphenhydramine) and an analgesic (ketorolac) as well as intravenous fluids. Subjects
      assigned to the experimental group (Propofol) will receive the same intravenous fluids and up
      to five doses of propofol. All subjects will undergo assessment of their pain (self-rated on
      a scale from 0-10) before and after treatment. During treatment they will have close
      monitoring of their vital signs. No additional laboratory tests or procedures are involved.
      Post-visit clinical data will be collected from the subject's medical record and subjects
      will be called by telephone 24-48 hours after discharge from the emergency department to ask
      how they are doing and whether they required any additional treatments such as home
      medications or by other medical professionals other than OHSU.

      The study data will be presented in summary tables that outline subjects' clinical
      presentation prior to treatments, and response to study drug during their visit. The main
      variables of interest include effectiveness (determined as a reduction in self-reported pain
      score), length of stay in the pediatric emergency department, recurrent headache requiring
      emergency treatment within 24 hours and whether any adverse effects occur. These will be
      compared between the 2 study groups with basic statistics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Self-Assessed Pain</measure>
    <time_frame>15 minutes after administration</time_frame>
    <description>Percent pain change after initial treatment using 10 point VAS scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rebound Headache at 24 Hour Follow-up Phone Call</measure>
    <time_frame>24 hours</time_frame>
    <description>Percentage of subjects reporting recurrence of headache with pain greater than at time of discharge from Emergency Department</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency Department Length of Stay</measure>
    <time_frame>Duration of stay in Emergency Department in Minutes</time_frame>
    <description>Length of stay from administration of medication to Emergency Department discharge in minutes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Migraine Headache</condition>
  <arm_group>
    <arm_group_label>Experimental Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol at subanesthetic dose via IV push</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metaclopramide in combination with ketorolac and diphenhydramine via IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses</description>
    <arm_group_label>Experimental Treatment Group</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Treatment</intervention_name>
    <description>Ketorolac, Diphenhydramine and Metoclopramide</description>
    <arm_group_label>Standard Treatment Group</arm_group_label>
    <other_name>NSAIDs / Dopamine Antagonists</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children 7-18 years of age

          -  Acute Migraine Headache

        Exclusion Criteria:

          -  Head Trauma

          -  CNS infection

          -  CNS tumor

          -  Previous CNS surgery or device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Garth D Meckler, MD, MSHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Sheridan, MD</last_name>
    <role>Study Director</role>
    <affiliation>sheridda@ohsu.edu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>May 22, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2012</study_first_posted>
  <results_first_submitted>April 4, 2018</results_first_submitted>
  <results_first_submitted_qc>December 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 31, 2018</results_first_posted>
  <last_update_submitted>December 5, 2018</last_update_submitted>
  <last_update_submitted_qc>December 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Garth Meckler</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Migraine Headache</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Dopamine Antagonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental Treatment Group</title>
          <description>Propofol at subanesthetic dose via IV push
Propofol: Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses
Total enrollment = 37 subjects</description>
        </group>
        <group group_id="P2">
          <title>Standard Treatment Group</title>
          <description>Metaclopramide in combination with ketorolac and diphenhydramine via IV infusion
Standard Treatment: Ketorolac, Diphenhydramine and Metoclopramide
Total enrollment = 37 subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Repeat Visits Not Included in Analysis</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>1 patient excluded for repeat visit from ST arm 7 patients excluded for repeat visit from Experimental arm</population>
      <group_list>
        <group group_id="B1">
          <title>Experimental Treatment Group</title>
          <description>Propofol at subanesthetic dose via IV push
Propofol: Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses</description>
        </group>
        <group group_id="B2">
          <title>Standard Treatment Group</title>
          <description>Metaclopramide in combination with ketorolac and diphenhydramine via IV infusion
Standard Treatment: Ketorolac, Diphenhydramine and Metoclopramide</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.6" spread="2.1"/>
                    <measurement group_id="B2" value="14.6" spread="3.0"/>
                    <measurement group_id="B3" value="14.6" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Self-Assessed Pain</title>
        <description>Percent pain change after initial treatment using 10 point VAS scale</description>
        <time_frame>15 minutes after administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Treatment Group</title>
            <description>Propofol at subanesthetic dose via IV push
Propofol: Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses
Total enrollment = 30 subjects</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment Group</title>
            <description>Metaclopramide in combination with ketorolac and diphenhydramine via IV infusion
Standard Treatment: Ketorolac, Diphenhydramine and Metoclopramide
Total enrollment = 36 subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Self-Assessed Pain</title>
          <description>Percent pain change after initial treatment using 10 point VAS scale</description>
          <units>percentage change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rebound Headache at 24 Hour Follow-up Phone Call</title>
        <description>Percentage of subjects reporting recurrence of headache with pain greater than at time of discharge from Emergency Department</description>
        <time_frame>24 hours</time_frame>
        <population>Percentage of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Treatment Group</title>
            <description>Propofol at subanesthetic dose via IV push
Propofol: Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses
Total enrollment = 30 subjects</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment Group</title>
            <description>Metaclopramide in combination with ketorolac and diphenhydramine via IV infusion
Standard Treatment: Ketorolac, Diphenhydramine and Metoclopramide
Total enrollment = 36 subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Rebound Headache at 24 Hour Follow-up Phone Call</title>
          <description>Percentage of subjects reporting recurrence of headache with pain greater than at time of discharge from Emergency Department</description>
          <population>Percentage of participants</population>
          <units>Percentage of subjects reporting rebound</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emergency Department Length of Stay</title>
        <description>Length of stay from administration of medication to Emergency Department discharge in minutes</description>
        <time_frame>Duration of stay in Emergency Department in Minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Treatment Group</title>
            <description>Propofol at subanesthetic dose via IV push
Propofol: Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses
Total enrollment = 30 subjects</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment Group</title>
            <description>Metaclopramide in combination with ketorolac and diphenhydramine via IV infusion
Standard Treatment: Ketorolac, Diphenhydramine and Metoclopramide
Total enrollment = 36 subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Emergency Department Length of Stay</title>
          <description>Length of stay from administration of medication to Emergency Department discharge in minutes</description>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="22" upper_limit="460"/>
                    <measurement group_id="O2" value="111" lower_limit="42" upper_limit="630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Experimental Treatment Group</title>
          <description>Propofol at subanesthetic dose via IV push
Propofol: Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses</description>
        </group>
        <group group_id="E2">
          <title>Standard Treatment Group</title>
          <description>Metaclopramide in combination with ketorolac and diphenhydramine via IV infusion
Standard Treatment: Ketorolac, Diphenhydramine and Metoclopramide</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Extrapyramidal Symptoms</sub_title>
                <description>Extrapyramidal symptoms</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxemia</sub_title>
                <description>Transient self-resolved hypoxia to 89%</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Sheridan</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503 494-8311</phone>
      <email>sheridda@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

